Cardiex is a pioneering health technology company that specializes in developing advanced digital biomarkers and solutions for cardiovascular health monitoring. Their innovative approach focuses on providing comprehensive vascular health insights through cutting-edge technologies like the FDA-cleared SphygmoCor® system, which replaces traditional blood pressure measurement methods with more precise arterial health screening techniques.
The company’s solutions are designed to empower multiple stakeholders in the healthcare ecosystem, including providers, researchers, clinical trial teams, and patients. By offering point-of-care arterial health screening and remote patient monitoring capabilities, Cardiex enables more informed treatment decisions, accelerates drug development, and helps individuals actively participate in their health management. Their technology can evaluate arterial health, identify disease risk, track progression, and assess the effectiveness of medical interventions.
Cardiex has established partnerships with numerous prestigious medical institutions and research centers, including UCSF Medical Center, Mayo Clinic, Stanford Medicine, and pharmaceutical companies like AstraZeneca and Novartis. Their commitment to advancing cardiovascular health is evident through initiatives like the CARTESIAN Study, which explores the vascular consequences of COVID-19, demonstrating their dedication to using digital biomarkers to enhance medical understanding and patient care across various health conditions.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
